Detailed Program Corporate Sessions

Monday, 2 May 2022 | 12:15 – 13:45

South Hall 2B

12:15 – 13:45

Corporate Session Merz Pharmaceuticals GmbH:
Understanding Sialorrhea in PD: Impact on patients and their families

Chair: Stuart Isaacson (United States)

Sialorrhea: impact in PD patients and their families
Veronica Clark (United Kingdom)

Sialorrhea: an underacknowledged symptom in PD
Stuart Isaacson (United States)

Sialorrhea: practical approach of BoNT treatment
Bruno Bergmans (Belgium)

Sialorrhea: holistic approach on patients management
Veronica Clark (United Kingdom)

Sialorrhea: Q&A session
Stuart Isaacson (United States)

South Hall 2B

Tuesday, 3 May 2022 | 12:15 – 13:45

12:15 – 13:45

Corporate Session Britannia Pharmaceuticals Ltd:
Reframing the treatment paradigm – the rationale for earlier use of device-aided therapy in advanced Parkinson’s disease

Chair: Teus van Laar (Netherlands)

Welcome & introductions
Focus on the patient journey – how can we extend the quality-of-life window in PD?
Teus van Laar (The Netherlands)

Timing the transition to device-aided therapies – pros, cons and pitfalls in clinical practice
Norbert Kovács (Hungary)

The future of intrajejunal therapy – the rationale for levodopa sparing
Pirtošek Zvezdan (Slovenia)

The non-surgical approach to device-aided Parkinson’s disease management
József Szász (Romania)

Question & answer session with the faculty
Teus van Laar (The Netherlands)

South Hall 2A

12:15 – 13:45

Corporate Session Abbott: 
Access to care. Telehealth in Deep Brain Stimulation

Is tele-medicine beneficial and useful for movement disorder patients?
Alfonso Fasano (Canada)

Remote management of DBS systems enabling technologies
Daniel Weiss (Germany)

Modifying the long-term disease courses through individualized remote monitoring and programming
Cristina Torres Diaz (Spain)

Panel discussion

Closing remarks